Creating healthier futures for all

Dominique held roles of increasing responsibility in the pharmaceutical industry, holding positions in sales, marketing and strategy at local, regional and global levels.

Prior to joining Stallergenes Greer in 2012, Dominique Pezziardi gained his expertise in several therapeutic fields including fertility, growth hormones, diabetes, orphan diseases, cardiology and medical devices, within pharmaceutical companies including Ciba, Sanofi and Merck Serono.

He successfully managed global product launches, life cycle development plans, mature franchises relaunches, alliances with strategic partners or more recently, corporate strategy development.

He graduated from a business school in Bordeaux, France and trained in pharmaco-economy in Milano, Italy.

Amer Jaber has extensive international experience in the pharmaceutical industry. Prior to joining Stallergenes Greer, Amer Jaber was Head of Biotechnology Operations at R-Pharm where he was in charge of developing the long-term strategy and execution of in-house and external technical operations for chemistry manufacturing and controls (CMC) Development and Manufacturing. He was previously Head of Global Biotech Development and Manufacturing for Technical Operations and Managing Director of UCB Switzerland. Before joining UCB, he held roles of increasing responsibility in product development, quality and manufacturing at Mondobiotech, Serono International and Rivopharm.

He holds a PhD in Medicinal Organic Chemistry from the University of Geneva and has completed various executive leadership programs at Harvard Business School, IMD and Babson College.

She joined Stallergenes Greer in 2015, where she held increasing responsibilities. Catherine began her career in the media sector in France (Publiprint France Soir/Le Figaro Magazine, Emap) before working in a variety of sectors in the U.S. and Denmark. She also has experience working in healthcare communication agencies including Vivactis Medical Education and Ogilvy Commonhealth (WPP network). 

Catherine holds a master’s degree in literature from Sorbonne University-Paris IV.

Elena has gained extensive expertise in drug development and the launch of new entities in dermatology, immunology, oncology, the central nervous system and infectious and cardiovascular diseases. Elena has significant leadership experience and has led complex cross-country matrix teams in medical, clinical, regulatory affairs, pharmacovigilance as well as in medical information and communication.

In her most recent role as VP and Head of the Intercontinental Region, Elena oversaw Biogen’s medical teams and neuroscience portfolio based in Switzerland. She previously served as Global Head of Medical Affairs for Dermatology at Sanofi Genzyme based in the US. Prior to joining Sanofi Genzyme, Elena held several leadership roles at Johnson & Johnson Innovation Asia Pacific, Janssen based in Europe and Asia, 3M Pharmaceutical based in Europe and Galderma based in France.

Elena Rizova is a medical doctor and a board-certified dermatologist with a PhD in immunology. 

Pascal Demoly is a respiratory physician and allergist, Professor of Pulmonology (since 2002) and Head of Department at the University Hospital of Montpellier, France (since 2010). He is the director of the INSERM - INRIA research unit IDESP (since 2021) focusing on epidemiology and public health of chronic non communicable diseases, massive health and environmental data, and modern mathematics. He is currently the president of the French Allergy Society (2022-2024, as in 2010-2012); he has chaired the French National Council for Allergology (2019-2021). In addition, he is a member of several national and international editorial boards of allergy journals and a full member of the French National Academy of Medicine. In the last years his research interest has focused mainly on allergy (rhinitis, asthma diagnosis and treatment, allergen immunotherapy, anaphylaxis and drug allergy) where he has extensive experience of lecturing. Prof. Demoly has published 950 articles including more than 600 in international peer-reviewed journals (H factor over 110 and citations over 63000, 2018 and 2021 Clarivate Analytics Highly Cited Researcher, category immunology) and is chair of the WHO Collaborating Center on Scientific Classification Support at the University Hospital of Montpellier (2018-2026).

Alessandro Fiocchi is an expert in the field of food allergy.

After post-graduate degrees and professional qualification in pediatrics, allergy, pulmonology, and neonatology, he dedicated his research and clinical work to the care of children with asthma and allergic disease. Currently, he leads a research group focusing on food allergy, asthma, and specific immunotherapy. This group is based in the Bambino Gesù Pediatric Hospital (OPBG) a health care and research institution specialized in pediatric and developing ages. The largest Pediatric Hospital in Italy, OPBG guarantees total coverage for all health care needs, including allergy.

Since 2001, he has organized international meetings in Milan, Italy, and other countries. He founded the Italian Research Foundation for Allergy and Asthma in Childhood – Allegria ONLUS, a charity dedicated to clinical and research studies. As chair of the Adverse Reactions to Foods Committee of the American College of Allergy, Asthma, and Immunology, he co-chaired with Sami Bahna and Amal Assa’ad several International Food Allergy Symposiums, the last in Anaheim, November 2012. He also co-chaired with Hugh Sampson the WAO Food Allergy Symposium in Bangkok, 2007, and in Buenos Aires, 2009. Starting in January 2008, Dr. Fiocchi is the chair of the Special Committee on Food Allergy of the World Allergy Organization. Under his chairmanship, WAO published the DRACMA guidelines on cow’s milk allergy in 2010 and the CUPPA position paper on the use of probiotics in pediatric allergy. He’s also the leader of the WAO – supported GLAD-p (GuideLines for Allergy Prevention) project, which published three guidelines so far (Probiotics, 2015; Prebiotics, 2016; Vitamin D, 2017). DRACMA is being be re-edited. His publications cover the fields of food allergy diagnosis, follow-up, epidemiology, specific immunotherapy and childhood asthma.

Dr Carla Irani is an Associate Professor of Medicine at St Joseph University. She is also a practicing clinician at Hotel-Dieu De France in Beirut. She completed her internal medicine residency at Cooper University Hospital, Camden, NJ, USA, followed by an allergy and clinical immunology fellowship at the Hospital of the University of Pennsylvania, Philadelphia, USA. Dr Irani also completed a Master of Clinical Epidemiology degree from the American University of Beirut.

Dr Irani’s clinical interests span asthma and allergy across both adult and paediatric medicine. She has a broad range of research interests and has published several papers in journals including the Journal of Allergy and Clinical Immunology on topics including the impact of pollution on allergic rhinitis, chronic urticaria and food allergy.

Dr Irani is a Fellow of the American Academy of Allergy, Asthma and Immunology and the President of the Lebanese Society of Allergy and Immunology. She is also an editorial board member for the International Archives of Allergy and Immunology.

Dr. Kari Nadeau practices Allergy, Asthma, Immunology in children and adults. She has published over 400 papers, many in the field of climate change and health. Dr. Nadeau, with a team of individuals and patients and families, has been able to help major progress and impact in the clinical fields of immunology, infection, asthma and allergy. Dr. Nadeau is a member of the National Academy of Medicine and the U.S. EPA Children’s Health Protection Committee.

For more than 30 years, she has devoted herself to understanding how environmental and genetic factors affect the risk of developing allergies and asthma, especially wildfire-induced air pollution. Her laboratory has been studying air pollution and wildfire effects on children and adults, including wildland firefighters. Many of the health issues involving individuals and the public are increasing because of global warming, sustainability practices, and extreme weather conditions. She oversees a team working on air pollution and wildfire research along with a multidisciplinary group of community leaders, firefighters, engineers, scientists, lawyers, and policy makers. Dr. Nadeau was appointed as a member of the U.S. Federal Wildfire Commission in 2022.

Dr. Nadeau works with other organizations and institutes across the world. She is working with the WHO on a scoping review and report for health ministers and policy makers on wildland fires: how to mitigate, adapt, and follow United Nation Sustainable Development Goals to create resiliency and co-benefits in communities, especially LMICs.

She also launched four biotech companies, and founded the Climate Change and Health Equity Task Force and started the Sustainability Health Seed Grant initiative and Climate Change and Health Fellowship program at Stanford. She also developed climate change and health courses at Stanford. She also has served on the Scientific Advisory Board of the U.S. EPA.

Dr. Nadeau earned her MD/PhD from Harvard Medical School in 1995, completing her doctoral work in biochemistry and immunology, followed by a pediatric internship and residency at Boston Children’s Hospital (1995-1997). She moved to California for a fellowship in the Stanford-UCSF Allergy, Asthma, and Immunology Program (2003-2006), joining the Stanford Medical School faculty as an instructor, followed by promotions to assistant professor (2008), associate professor (2011), and professor (2015).